NCT01154127 - Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

NVA237

50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily

DRUG

Placebo

Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily

Trial Locations (10)

Spartanburg Medical Research, 485 Simuel Road, Spartanburg

Novartis Investigative Site, Berlin

Novartis Investigative Site, Frankfurt

Novartis Investigative Site, Mainz

Novartis Investigative Site, Mannheim

Novartis Investigative Site, Wiesbaden

Novartis Investigative Site, Woehrendamm

Novartis Investigative Site, Verona

Novartis Investigative Site, Bucharest

Novartis Investigative Site, Manchester